Repurposing glucose-lowering drugs for cancer therapy DOI Creative Commons
Michaela Luconi, Giulia Cantini, Clara Crescioli

et al.

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

The acknowledged relationship between metabolism and cancer retains important potential as a novel target in therapy. Reallocating glucose-lowering drugs (GLDs) treatment offers valuable perspectives for the ability of these molecules to regulate at cellular systemic level. This comprehensive review addresses therapeutic main antidiabetic classes with emerging anticancer effects, such metformin, rosiglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium/glucose cotransporter-2 inhibitors. multifaceted actions are explored, from vitro evidence clinical monotherapy or sparing agent chemotherapy immunotherapy. For each molecule, unconventional mechanisms, benefits, limitations dissected possible concerns addressed, supporting use drug cancer.

Language: Английский

Research Progress of SGLT2 Inhibitors in Cancer Treatment DOI Creative Commons

Xiaoyong Miao,

Jianing Zhang,

Weiyan Huang

et al.

Drug Design Development and Therapy, Journal Year: 2025, Volume and Issue: Volume 19, P. 505 - 514

Published: Jan. 1, 2025

Sodium glucose co-transporter 2 (SGLT2) inhibitors represent a novel class of hypoglycemic drugs that have emerged in recent years. These function primarily by blocking the reabsorption kidneys, specifically targeting SGLT2 proteins proximal convoluted tubules. This inhibition results reduction blood levels through increased excretion urine. Recent studies identified expression various cancer types, suggesting can potentially suppress tumor growth. article provides comprehensive review role tumorigenesis and progression, explores underlying mechanisms potential therapeutic applications as anticancer agents.

Language: Английский

Citations

1
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents DOI Creative Commons
Yogita Dhas, Nupur Biswas,

M R Divyalakshmi

et al.

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: Sept. 28, 2024

Abstract Drug repurposing in cancer taps into the capabilities of existing drugs, initially designed for other ailments, as potential treatments. It offers several advantages over traditional drug discovery, including reduced costs, development timelines, and a lower risk adverse effects. However, not all classes align seamlessly with patient's condition or long-term usage. Hence, chronically used drugs presents more attractive option. On hand, metabolic reprogramming being an important hallmark paves regulators possible therapeutics. This review emphasizes importance current insights antidiabetic metformin, sulfonylureas, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) glucagon-like peptide-1 receptor agonists (GLP-1RAs), thiazolidinediones (TZD), α-glucosidase against various types cancers. Antidiabetic regulating pathways have gained considerable attention research. The literature reveals complex relationship between risk. Among metformin may possess anti-cancer properties, potentially reducing cell proliferation, inducing apoptosis, enhancing sensitivity to chemotherapy. revealed heterogeneous responses. Sulfonylureas TZDs demonstrated consistent activity, while SGLT2 inhibitors DPP-4 shown some benefits. GLP-1RAs raised concerns due associations increased certain highlights that further research is warranted elucidate mechanisms underlying effects these establish their efficacy safety clinical settings.

Language: Английский

Citations

7
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2) DOI Creative Commons
Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко

et al.

Innovative medicine of Kuban, Journal Year: 2025, Volume and Issue: 10(1), P. 101 - 109

Published: Feb. 26, 2025

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now uncovering new possibilities in the field of internal medicine owing to their diverse protective effects. In second part literature review, we explore potential applications SGLT2i hepatology, neurology, ophthalmology, and oncology, mechanisms action such drugs as dapagliflozin, empagliflozin, canagliflozin, etc, effect on different organs systems.

Language: Английский

Citations

0
Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology DOI Creative Commons
Iacob-Daniel Goje, Greta Ionela Barbulescu,

Valentin Ordodi

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 681 - 681

Published: May 3, 2025

Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone hematologic malignancy treatment, but it limited by its dose-dependent cardiotoxicity, to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as subspecialty addressing cardiovascular complications in cancer patients, highlighting preventive therapeutic strategies reduce therapy-related (CTRCD). Current approaches, including beta-blockers, renin–angiotensin system (RAS) inhibitors, statins, offer partial cardioprotection. Sodium-glucose cotransporter-2 (SGLT2) initially developed for type 2 diabetes mellitus (T2DM), demonstrate pleiotropic cardioprotective effects beyond glycemic control, reduced oxidative stress, inflammation, myocardial remodeling. This review explores interplay between anthracycline therapy, particularly DOX, cardiotoxicity while evaluating SGLT2 inhibitors novel agents cardio-oncology. Preclinical studies suggest attenuate CTRCD preserving mitochondrial function inhibiting apoptosis, clinical trials highlight their efficacy reducing heart failure (HF) hospitalizations (CV) mortality. Integrating into cardio-oncology protocols could revolutionize management CTRCD, enhancing patient outcomes oncology care. Considering emerging evidence, may provide significant benefits patients undergoing those with elevated risk profiles. We recommend that future prospective, large-scale further evaluate safety these therapy optimize individualized treatment strategies.

Language: Английский

Citations

0
Repurposing glucose-lowering drugs for cancer therapy DOI Creative Commons
Michaela Luconi, Giulia Cantini, Clara Crescioli

et al.

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

The acknowledged relationship between metabolism and cancer retains important potential as a novel target in therapy. Reallocating glucose-lowering drugs (GLDs) treatment offers valuable perspectives for the ability of these molecules to regulate at cellular systemic level. This comprehensive review addresses therapeutic main antidiabetic classes with emerging anticancer effects, such metformin, rosiglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium/glucose cotransporter-2 inhibitors. multifaceted actions are explored, from vitro evidence clinical monotherapy or sparing agent chemotherapy immunotherapy. For each molecule, unconventional mechanisms, benefits, limitations dissected possible concerns addressed, supporting use drug cancer.

Language: Английский

Citations

0